Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OriGene to Build mAb Production Facility in Wuxi

publication date: May 19, 2010
OriGene Technologies  announced plans to build one of the world’s largest monoclonal antibody production facilities in Wuxi, China. The center will be built “with the support” of the Wuxi Biopharmaceutical R&D Outsourcing Servicing Park, also known as BioPark. Specific details of the agreement were not disclosed. OriGene said the high-throughput production facility will eventually employ over one thousand people and have the capacity to produce more than 20,000 of the company’s TrueMAB™ antibodies per year. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here